Targeting the Sphingosine-1-Phosphate Axis for Developing Non-narcotic Pain Therapeutics.
Targeting the Sphingosine-1-Phosphate Axis for Developing Non-narcotic Pain Therapeutics.
复制标题
DOI:
10.1016/j.tips.2020.09.006
复制
发表时间:
2020-11
影响因子:
13.8
通讯作者:
Salvemini D
中科院分区:
文献类型:
--
作者:
Squillace S;Spiegel S;Salvemini D
Chronic pain is a life-altering condition affecting millions of people. Current treatments are inadequate and prolonged therapies come with severe side effects, especially dependence and addiction to opiates. Identification of non-narcotic analgesics is of paramount importance. Preclinical and clinical studies suggest that sphingolipid metabolism alterations contribute to neuropathic pain development. Functional S1P receptor 1 (S1PR1) antagonists, such as FTY720/Fingolimod, used clinically for non-pain conditions, are emerging as non-narcotic analgesics, supporting the repurposing of Fingolimod for chronic pain treatment and energizing drug discovery focused on S1P signalling. Here we summarize the role of sphingosine-1-phosphate (S1P) in pain to highlight the potential of targeting the S1P axis towards development of non-narcotic therapeutics which in turn will hopefully help lessen misuse of opioid pain medications and address the ongoing opioid epidemic.
登录
查看更多内容
影响因子:
6.7
作者:
Chua KC;Xiong C;Ho C;Mushiroda T;Jiang C;Mulkey F;Lai D;Schneider BP;Rashkin SR;Witte JS;Friedman PN;Ratain MJ;McLeod HL;Rugo HS;Shulman LN;Kubo M;Owzar K;Kroetz DL
通讯作者:
Kroetz DL
影响因子:
4.8
作者:
Doyle, Tim;Chen, Zhoumou;Salvemini, Daniela
通讯作者:
Salvemini, Daniela
影响因子:
4.6
作者:
Aoki M;Aoki H;Ramanathan R;Hait NC;Takabe K
通讯作者:
Takabe K
影响因子:
16.6
作者:
Corbett, Brian F.;Luz, Sandra;Bhatnagar, Seema
通讯作者:
Bhatnagar, Seema
影响因子:
6.2
作者:
Deora, Vandana;Lee, John D.;Woodruff, Trent M.
通讯作者:
Woodruff, Trent M.